What podcasts say about Kabir Nath
Every statement, with the speaker, the exact quote and the moment it was said.
What Kabir Nath has said on podcasts
12 statements · 11 positive · 1 neutral
Two or three annual psilocybin sessions may relieve depression symptoms for up to a year
“perhaps two or three day-long sessions in a year can give you relief from depression symptoms for up to a year”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 0:09
Natural psychedelic medicine settings will continue to exist
“the natural medicine world is going to continue to exist”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 23:23
- on Natural psychedelic medicine infrastructure in Oregon and ColoradoPositiveNov 22, 2026· Motley Fool Hidden Gems Investing
Natural psychedelic infrastructure will continue developing in Oregon and Colorado
“I expect to see that continue to develop”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 23:35
Spravato is on track for a $3–3.5 billion annualized run rate
“Spravato is on track to a three, three and a half billion dollar run rate”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 24:20
Psychedelics will develop transformative market potential like immuno-oncology
“I think you're going to see exactly the same with psychedelics”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 25:59
Psychedelic treatments will expand into currently untreated psychiatric conditions
“you're going to see movement from some of the traditional neuropsych areas, where we've all started, into areas where there is nothing used today”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:01
- on Psychedelic treatments for OCD, eating disorders, and substance-use disordersPositiveNov 22, 2026· Motley Fool Hidden Gems Investing
Potential psychedelic applications include OCD, eating disorders, and substance-use disorders
“Obsessive compulsive disorder, eating disorders, substance use disorders, and so on”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:11
Psychedelics will create a massive commercial opportunity
“I think this will be a massive opportunity”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:16
Compass may remain a leader in psychedelic medicine
“I would hope the Compass continues to be a leader in that field”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:18
Psychedelic treatment centers will proliferate with varied operating models
“you will see many, many different treatment centers, a range of different models”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:39
- on Psychedelic treatment-center infrastructurePositiveNov 22, 2026· Motley Fool Hidden Gems Investing
Corporate investment will enter psychedelic treatment-center infrastructure
“I think you're going to see a lot of corporate money coming into that side”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 26:45
Treatment-resistant depression may eventually cease to exist
“this idea of treatment-resistant depression no longer exists”
Open the episode · The FDA Is About to Rule on Psilocybin Therapy — Here’s What Investors Need to KnowListen at 27:01
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.